See more : Freehold Royalties Ltd. (FRU.TO) Income Statement Analysis – Financial Results
Complete financial analysis of IntelGenx Technologies Corp. (IGXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IntelGenx Technologies Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Japan Craft Holdings Co., Ltd. (7135.T) Income Statement Analysis – Financial Results
- BC Technology Group Limited (0863.HK) Income Statement Analysis – Financial Results
- ClearPoint Neuro, Inc. (CLPT) Income Statement Analysis – Financial Results
- Reabold Resources Plc (RBD.L) Income Statement Analysis – Financial Results
- American Video Teleconferencing Corp. (AVOT) Income Statement Analysis – Financial Results
IntelGenx Technologies Corp. (IGXT)
About IntelGenx Technologies Corp.
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 950.00K | 1.54M | 1.54M | 742.00K | 1.82M | 5.20M | 5.22M | 5.10M | 1.66M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 1.86M | 2.26M | 1.48M | 0.00 | 0.00 | 373.00K | 319.00K | 433.00K | 61.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -694.00K | -908.00K | -721.00K | 67.00K | 742.00K | 1.82M | 4.82M | 4.90M | 4.66M | 1.60M | 948.00K | 1.21M | 440.00K | 1.34M | 1.28M | 976.61K | 835.42K | 265.90K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -66.79% | -95.58% | -46.97% | 4.34% | 100.00% | 100.00% | 92.82% | 93.89% | 91.50% | 96.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.43M | 3.03M | 2.72M | 2.64M | 3.77M | 5.10M | 2.62M | 1.77M | 1.03M | 1.08M | 561.00K | 1.72M | 1.34M | 1.57M | 1.42M | 2.09M | 603.40K | 510.41K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.76M | 4.70M | 3.75M | 4.44M | 5.80M | 5.00M | 3.97M | 3.61M | 2.07M | 2.29M | 1.95M | 1.65M | 1.51M | 2.73M | 1.38M | 1.46M | 919.62K | 488.60K | 9.91K | 7.55K | 108.00 |
| Other Expenses | 0.00 | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | -237.90K | -376.84K | -132.37K | 33.91K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.18M | 8.51M | 7.26M | 7.81M | 10.29M | 10.82M | 7.32M | 5.88M | 3.28M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Cost & Expenses | 10.68M | 10.36M | 9.52M | 7.81M | 10.29M | 10.82M | 7.69M | 6.20M | 3.71M | 3.44M | 2.59M | 3.41M | 2.89M | 4.34M | 2.57M | 3.17M | 1.57M | 1.03M | 9.91K | 7.55K | 108.00 |
| Interest Income | 41.00K | 4.00K | 152.00K | 422.00K | 97.00K | 11.00K | 11.00K | 4.00K | 28.00K | 34.00K | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | 30.86K | 27.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.28M | 1.49M | 1.20M | 1.21M | 1.12M | 569.00K | 203.00K | 123.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | 784.40K | 766.14K | 349.11K | 54.72K | 1.22K | 297.00 | 0.00 |
| Depreciation & Amortization | 766.00K | 777.00K | 791.00K | 734.00K | 718.00K | 719.00K | 735.00K | 511.00K | 171.00K | 74.00K | 72.00K | 46.00K | 37.00K | 44.00K | 44.60K | 51.77K | 42.01K | 33.91K | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.69M | -8.64M | -7.04M | -5.11M | -8.74M | -8.28M | -1.76M | -470.00K | 1.59M | -1.71M | -1.57M | -2.22M | -2.60M | -3.14M | -1.24M | -2.45M | -948.17K | -731.53K | -146.53K | -7.55K | -108.00 |
| EBITDA Ratio | -739.65% | -908.63% | -458.57% | -330.83% | -1,177.22% | -453.29% | -33.63% | -8.93% | 31.11% | -102.83% | -165.30% | -178.81% | -547.50% | -221.24% | -97.11% | -219.13% | -68.71% | -290.98% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.49M | -9.41M | -7.98M | -6.26M | -9.55M | -9.00M | -2.49M | -981.00K | 1.39M | -1.78M | -1.64M | -2.21M | -2.45M | -3.00M | -1.29M | -2.19M | -729.62K | -767.02K | -9.91K | -7.55K | -108.00 |
| Operating Income Ratio | -913.47% | -990.84% | -520.00% | -405.70% | -1,287.06% | -493.31% | -47.99% | -18.79% | 27.20% | -107.29% | -172.89% | -182.62% | -555.91% | -224.53% | -100.60% | -224.43% | -87.34% | -288.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -436.00K | -1.28M | -1.34M | -780.00K | -1.11M | -1.11M | -558.00K | -199.00K | -95.00K | 34.00K | 0.00 | 10.00K | 172.00K | -558.00K | -686.70K | -306.67K | -196.81K | -14.12K | 35.29K | 0.00 | 0.00 |
| Income Before Tax | -9.93M | -10.69M | -9.32M | -7.04M | -10.66M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -2.07M | -2.96M | -1.16M | -781.14K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -955.44% | -1,125.26% | -607.04% | -456.22% | -1,436.66% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -161.94% | -302.88% | -139.44% | -293.77% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.28M | -6.00K | 1.20M | 1.21M | 11.00K | 11.00K | 4.00K | 28.00K | 0.00 | 0.00 | 3.00K | 3.00K | 98.00K | -130.30K | -151.58K | -64.08K | 14.12K | 11.12K | 7.84K | 108.00 |
| Net Income | -9.93M | -11.97M | -9.31M | -8.25M | -11.87M | -10.11M | -3.05M | -1.18M | 1.29M | -1.75M | -1.64M | -2.25M | -2.45M | -3.10M | -1.94M | -2.81M | -1.10M | -781.14K | -11.12K | -7.84K | -108.00 |
| Net Income Ratio | -955.44% | -1,259.68% | -606.64% | -534.07% | -1,599.33% | -554.17% | -58.73% | -22.61% | 25.34% | -105.24% | -172.89% | -186.26% | -557.27% | -231.56% | -151.75% | -287.36% | -131.77% | -293.77% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.07 | -0.08 | -0.13 | -0.14 | -0.05 | -0.02 | 0.01 | -0.03 | -0.03 | -0.05 | -0.06 | -0.09 | -0.08 | -0.14 | -0.07 | -0.05 | 0.00 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 63.52M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
| Weighted Avg Shares Out (Dil) | 174.65M | 164.75M | 137.00M | 108.44M | 93.53M | 74.12M | 66.15M | 63.96M | 70.86M | 63.18M | 54.02M | 49.64M | 43.74M | 35.33M | 24.53M | 19.66M | 16.04M | 14.34M | 10.99M | 1.50M | 1.50M |
IntelGenx to Report Second Quarter 2023 Financial Results on August 14, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, Aug. 07, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its second quarter 2023 financial results after market close on Monday, August 14, 2023.
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson's Disease
- Manufacturing of both active and placebo films underway for planned 18-month study - - Manufacturing of both active and placebo films underway for planned 18-month study -
IntelGenx Announces a Change to its Board of Directors
SAINT-LAURENT, Quebec, July 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Mr. J. Bernard (Bernie) Boudreau from the Board of Directors (the “Board”) of the Company effective today. Mr. Boudreau was...
IntelGenx Announces Voting Results on Election of Directors
SAINT LAURENT, Quebec, July 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of the Company held on May 9, 2023 (the “Annual Meeting”), shareholders voted in...
IntelGenx Technologies Corp. (IGXT) Q1 2023 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Horst Zerbe - Chief Executive Officer Andre Godin - President and Chief Financial Officer David Kideckel - Head-Corporate...
IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, May 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2023 financial results after market close on Thursday, May 11, 2023.
IntelGenx Technologies Corp. (IGXT) Q4 2022 Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Horst Zerbe – Chief Executive Officer Andre Godin – President and Chief Financial Officer Frank Pietrantonio – Director-Clinical...
IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023
SAINT LAURENT, Quebec, March 24, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter...
IntelGenx to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 – Conference Call to Follow
SAINT LAURENT, Quebec, March 23, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its fourth quarter and full year 2022 financial results after market close on Thursday,...
IntelGenx Technologies Corp. (IGXT) Q3 2022 - Earnings Call Transcript
IntelGenx Technologies Corp. (OTCQB:IGXT) Q3 2022 Earnings Conference Call November 11, 2022 8:00 PM ET Company Participants Stephen Kilmer - Investor Relations Horst Zerbe - Chief Executive Officer André Godin - President and Chief Financial Officer Dana Matzen - Vice...
Source: https://incomestatements.info
Category: Stock Reports